Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Capricor Therapeutics's Sloan Ratio for the quarter that ended in Mar. 2026 was 18.11%.
Warning Sign:
When sloan ratio (-37.28)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.
As of Mar. 2026, Capricor Therapeutics has a Sloan Ratio of 18.11%, indicating earnings are more likely to be made up of accruals.
Capricor Therapeutics (NAS:CAPR) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2026, Capricor Therapeutics has a Sloan Ratio of 18.11%, indicating earnings are more likely to be made up of accruals.
Capricor Therapeutics Sloan Ratio % Related Terms
Capricor Therapeutics Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Capricor Therapeutics's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAPR vs COAG, DMRA, MPLT: Sloan Ratio % Comparison
For the Biotechnology subindustry, Capricor Therapeutics's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Capricor Therapeutics Sloan Ratio % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Capricor Therapeutics's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Capricor Therapeutics's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
Capricor Therapeutics's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was -25.911 (Jun. 2025 ) + -24.571 (Sep. 2025 ) + -30.171 (Dec. 2025 ) + -33.941 (Mar. 2026 ) = $-114.59 Mil.
Capricor Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was -20.122 (Jun. 2025 ) + -19.689 (Sep. 2025 ) + -23.567 (Dec. 2025 ) + -29.255 (Mar. 2026 ) = $-92.63 Mil.
Capricor Therapeutics's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 was 14.549 (Jun. 2025 ) + 15.951 (Sep. 2025 ) + 43.088 (Dec. 2025 ) + -154.642 (Mar. 2026 ) = $-81.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capricor Therapeutics (CAPR) has a Sloan Ratio % of 18.11% as of Mar. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Capricor Therapeutics and its competitors.
Is Capricor Therapeutics' Sloan Ratio % too high?
Capricor Therapeutics' current Sloan Ratio % is 18.11%. Overall, Capricor Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' Sloan Ratio % compare to COAG and DMRA?
Capricor Therapeutics' Sloan Ratio % of 18.11% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Biotechnology company?
A good Sloan Ratio % depends on the Biotechnology industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Capricor Therapeutics and its competitors. Capricor Therapeutics's current Sloan Ratio % is 18.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Capricor Therapeutics (CAPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.87, compared to a current price of $19.12 — trading 292.6% above its estimated fair value. The current Sloan Ratio % is 18.11%. Capricor Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Capricor Therapeutics (CAPR), the current Sloan Ratio % is 18.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Capricor Therapeutics (CAPR) Overvalued in 2026?
Based on GuruFocus' analysis, Capricor Therapeutics stock appears to be overvalued.
The current stock price of $19.12 is trading 292.6% above its estimated GF Value™ of $4.87.
GuruFocus considers Capricor Therapeutics to be Significantly Overvalued.
Key valuation signals for CAPR:
Sloan Ratio %: 18.11%
GF Value™: $4.87 vs. price of $19.12 (292.6% above fair value)
No single metric tells the full story. See the CAPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
37GF Score
Get the complete analysis for CAPR
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAPR has been successfully added to your 
